Bausch Health Cos (BHC) Stock Price, News & Analysis

Company Overview

Bausch Health Companies Inc. (NYSE:BHC) is a multinational specialty pharmaceutical company focused on developing, manufacturing and commercializing branded, generic and over-the-counter medicines. Its portfolio serves several therapeutic areas, including gastroenterology, dermatology, neurology, ophthalmology, hospital products and other specialty-care markets.

The company markets products through businesses such as Salix Pharmaceuticals, Ortho Dermatologics, Solta Medical and its international pharmaceutical operations. Its products are sold in the United States and internationally through a combination of direct commercial operations, distributors and strategic partners.

Bausch Health was previously known as Valeant Pharmaceuticals International and adopted its current name in 2018. In 2022, it separated its eye-care business, Bausch + Lomb, into a separately traded public company. Bausch Health is headquartered in Laval, Quebec, and is led by Chief Executive Officer Thomas J. Appio.

Key Stats

• Today's Range: $6.20 to $6.49
• 50-Day Range: $5.64 to $6.94
• 52-Week Range: $4.33 to $8.00
• Volume: 2.43 million shs
• Average Volume: 1.80 million shs
• Market Capitalization: $2.41 billion
• P/E Ratio: 1.52
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Hold

Bausch Health Cos Stock Analysis - MarketRank™

Bausch Health Cos scored higher than 58% of companies evaluated by MarketBeat, and ranked 524th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Bausch Health Cos has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 strong buy rating, no buy ratings, 5 hold ratings, and 1 sell rating.

Upside Potential

Bausch Health Cos has a consensus price target of $8.00, representing about 24.1% upside from its current price of $6.45.

Amount of Analyst Coverage

Bausch Health Cos has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -7.59%

Earnings Growth

Earnings for Bausch Health Cos are expected to decrease by -7.59% in the coming year, from $4.35 to $4.02 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bausch Health Cos is 1.52, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.76.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bausch Health Cos is 1.52, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.67.

Price to Book Value per Share Ratio

Bausch Health Cos has a P/B Ratio of 6.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.83% of the float of Bausch Health Cos has been sold short.

Short Interest Ratio / Days to Cover

Bausch Health Cos has a short interest ratio ("days to cover") of 4.83.

Change versus previous month

Short interest in Bausch Health Cos has recently decreased by 2.59%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bausch Health Cos does not currently pay a dividend.

Dividend Growth

Bausch Health Cos does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Bausch Health Cos this week, compared to 3 articles on an average week.

Search Interest

Only 2 people have searched for BHC on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

1 people have added Bausch Health Cos to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Bausch Health Cos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $258,894.00 in company stock.

Percentage Held by Insiders

20.67% of the stock of Bausch Health Cos is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

78.65% of the stock of Bausch Health Cos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/29/2026
• Today: 10/23/2026
• Next Earnings (Estimated): 10/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:BHC
• CIK: 885590
• Web: www.bauschhealth.com
• Phone: (514) 744-6792
• Fax: 514-744-6272
• Employees: 20,300
• Year Founded: 1959

Price Target and Rating

• Average Price Target for Bausch Health Cos: $8.00
• High Price Target: $9.00
• Low Price Target: $7.00
• Potential Upside/Downside: +24.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.14
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 1.48
• P/E Growth: N/A
• Net Income: $157 million
• Net Margins: -10.12%
• Pretax Margin: -6.74%
• Return on Equity: -561.95%
• Return on Assets: 6.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.44
• Quick Ratio: 1.08

Sales & Book Value

• Annual Sales: $10.27 billion
• Price / Sales: 0.24
• Cash Flow: $7.24 per share
• Price / Cash Flow: 0.89
• Book Value: $1.02 per share
• Price / Book: 6.32

Miscellaneous

• Outstanding Shares: 374,380,000
• Free Float: 296,998,000
• Market Cap: $2.41 billion
• Optionable: Optionable
• Beta: 0.37